AI assistant
Sending…
4D Molecular Therapeutics, Inc. — Director's Dealing 2021
Jun 10, 2021
33060_dirs_2021-06-09_ce76b0c6-c264-4d5c-a352-46472b880616.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: 4D Molecular Therapeutics Inc. (FDMT)
CIK: 0001650648
Period of Report: 2021-06-07
Reporting Person: Zimmermann Carolyne (Chief Business Officer)
More from 4D Molecular Therapeutics, Inc.
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 18
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Regulatory Filings
2026
Jan 26
Director's Dealing
2026
Jan 8